Delcath Systems Inc. (DCTH)
NASDAQ: DCTH
· Real-Time Price · USD
15.39
0.05 (0.33%)
At close: Jun 16, 2025, 3:59 PM
15.46
0.42%
After-hours: Jun 16, 2025, 07:54 PM EDT
0.33% (1D)
| Bid | 14.77 |
| Market Cap | 536.15M |
| Revenue (ttm) | 52.21M |
| Net Income (ttm) | -14.21M |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -34.21 |
| Forward PE | 23.97 |
| Analyst | Strong Buy |
| Ask | 15.62 |
| Volume | 486,009 |
| Avg. Volume (20D) | 492,653 |
| Open | 15.48 |
| Previous Close | 15.34 |
| Day's Range | 14.96 - 15.48 |
| 52-Week Range | 7.17 - 18.23 |
| Beta | 0.93 |
About DCTH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DCTH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DCTH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-6.32%
DCTH stock has given up its prior gain. Delcath Sy...
Unlock content with
Pro Subscription
3 weeks ago
-6.32%
Delcath Systems shares are trading higher after the company issued FY25 guidance and provided business updates.
4 weeks ago · seekingalpha.com
Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To ExecutionDelcath's commercial execution post-HEPZATO launch has driven impressive revenue growth, positive cash flow, and a shift from speculative to established biotech. Q1 earnings beat expectations with 530...
1 month ago · businesswire.com
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
